External Beam Radiotherapy for Thyroid Cancer

Part of the Head and Neck Cancer Clinics book series (HNCC)


Treatment of differentiated thyroid cancer (DTC) most often involves a combination of surgery, radioactive iodine (RAI) and suppression of thyroid-stimulating hormone (TSH). In specific situations, external beam radiotherapy (EBRT) could be of benefit, although this remains controversial because of a lack of randomized evidence to support its use. In contrast, EBRT is of standard use in the multimodal management of anaplastic thyroid cancer (ATC) with surgery and systemic agents. Despite this, outcomes remain poor, supporting the need for additional research of this devastating disease. This chapter focuses on the role of EBRT in DTC and ATC.


Thyroid Cancer Differentiate Thyroid Cancer Tracheal Stenosis Anaplastic Thyroid Cancer American Thyroid Association 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Farahati J, Reiners C, Stuschke M, et al. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pt4). Cancer. 1996;77:172–80.PubMedCrossRefGoogle Scholar
  2. 2.
    Tubiana M, Haddad E, Schlumberger M, et al. External radiotherapy in thyroid cancers. Cancer. 1985;55(9 Suppl):2062–71.PubMedCrossRefGoogle Scholar
  3. 3.
    Tsang RW, Brierley JD, Simpson WJ, et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer. 1998;82:375–88.PubMedCrossRefGoogle Scholar
  4. 4.
    Terezakis SA, Lee KS, Ghossein RA, et al. Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys. 2009;73:795–801.PubMedCrossRefGoogle Scholar
  5. 5.
    Schwartz DL, Lobo MJ, Ang KK, et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys. 2009;74:1083–91.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    O’Connell ME, A’Hern RP, Harmer CL. Results of external beam radiotherapy in differentiated thyroid carcinoma: a retrospective study from the Royal Marsden Hospital. Eur J Cancer. 1994;30A:733–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Biermann M, Pixberg M, Riemann B, et al. Clinical outcomes of adjuvant externalbeam radiotherapy for differentiated thyroid cancer—results after 874 patient-years of follow-up in the MSDS-trial. Nuklearmedizin. 2009;48:89–98; quiz N15.PubMedGoogle Scholar
  8. 8.
    American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.CrossRefGoogle Scholar
  9. 9.
    British Thyroid Association, Royal College of Physicians. Guidelines for the management of thyroid cancer. In: Perros P, editor. Report of the thyroid cancer guidelines update group. 2nd ed. London: Royal College of Physicians; 2007.Google Scholar
  10. 10.
    Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (parsport): a phase 3 multicentre randomised controlled trial. Lancet Oncology. 2011;12:127–36.PubMedCrossRefGoogle Scholar
  11. 11.
    Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensitymodulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25:4873–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Nutting CM, Convery DJ, Cosgrove VP, et al. Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland. Radiother Oncol. 2001;60:173–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Azrif M, Slevin NJ, Sykes AJ, et al. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation. Radiother Oncol. 2008;89:105–13.PubMedCrossRefGoogle Scholar
  14. 14.
    Ford D, Giridharan S, McConkey C, et al. External beam radiotherapy in the management of differentiated thyroid cancer. Clin Oncol (R Coll Radiol). 2003;15:337–41.CrossRefGoogle Scholar
  15. 15.
    Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 2010;22:486–97.CrossRefGoogle Scholar
  16. 16.
    Haigh PI, Ituarte PH, Wu HS, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer. 2001;91:2335–42.PubMedCrossRefGoogle Scholar
  17. 17.
    Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22:1104–39.PubMedCrossRefGoogle Scholar
  18. 18.
    Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103:1330–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Wang Y, Tsang R, Asa S, et al. Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer. 2006;107:1786–92.Google Scholar
  20. 20.
    Dandekar P, Harmer C, Barbachano Y, et al. Hyperfractionated accelerated radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis. Int J Radiat Oncol Biol Phys. 2009;74:518–21.PubMedCrossRefGoogle Scholar
  21. 21.
    De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60:1137–43.PubMedCrossRefGoogle Scholar
  22. 22.
    Swaak-Kragten AT, de Wilt JH, Schmitz PI, et al. Multimodality treatment for anaplastic thyroid carcinoma—treatment outcome in 75 patients. Radiother Oncol. 2009;92:100–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Troch M, Koperek O, Scheuba C, et al. High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab. 2010;95:E54–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011;21:25–30.PubMedCrossRefGoogle Scholar
  25. 25.
    Higashiyama T, Ito Y, Hirokawa M, et al. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid. 2010;20:7–14.PubMedCrossRefGoogle Scholar
  26. 26.
    Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid. 2009;19:233–40.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Ha HT, Lee JS, Urba S, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid. 2010;20:975–80.PubMedCrossRefGoogle Scholar
  28. 28.
    Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714–9.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© K. Alok Pathak, Richard W. Nason, Janice L. Pasieka, Rehan Kazi, Raghav C. Dwivedi 2015

Authors and Affiliations

  1. 1.Radiation OncologyCancerCare ManitobaWinnipegCanada

Personalised recommendations